Association of High Expression of Groβ with Clinical and Pathological Characteristics of Unfavorable Prognosis in Gastrointestinal Stromal Tumors

Table 2

Association of GROβ expression with clinical characteristics of GIST.

Groups	Number	Cytoplasm staining of GROβ				Nucleus staining of GROβ
		Low/0 (%)	High (%)	Pearson		Low/0 (%)	High (%)	Pearson
Total	173	117 (67.6)	56 (32.4)			109 (63.0)	64 (37.0)
Age
60 years	89	52 (58.4)	37 (41.6)	4.108	0.043^*	49 (55.1)	40 (44.9)	2.185	0.139
60 years	69	51 (73.9)	18 (26.1)			46 (66.7)	23 (33.3)
Unknown	15	14 (93.3)	1 (6.7)			14 (93.3)	1 (6.7)
Tumor size
5 cm	42	31 (73.8)	11 (26.2)	1.529	0.466	27 (64.3)	15 (35.7)	3.798	0.150
5–10 cm	72	46 (63.9)	26 (36.1)			46 (63.9)	26 (36.1)
10 cm	37	23 (62.2)	14 (37.8)			17 (45.9)	20 (54.1)
Unknown	22	17 (77.3)	5 (22.7)			19 (86.4)	3 (13.6)
Mitotic index (per 50 HPFs)
0–5	64	45 (70.3)	19 (29.7)	1.288	0.256	44 (68.7)	20 (31.3)	4.502	0.034^*
6	80	49 (61.2)	31 (38.8)			41 (51.2)	39 (48.8)
Unknown	29	23 (79.3)	6 (20.7)			24 (82.8)	5 (17.2)
Growth pattern
Single nodule	136	89 (65.4)	47 (34.6)	0.038	0.845	85 (62.5)	51 (37.5)	1.599	0.206
Multiple	19	12 (63.2)	7 (36.8)			9 (47.4)	10 (52.6)
Unknown	18	16 (88.9)	2 (11.1)			15 (83.3)	3 (16.7)
Location
Stomach	75	58 (77.2)	17 (22.7)	8.588	0.014^*	52 (69.3)	23 (30.7)	6.035	0.049^*
Intestine	61	33 (54.1)	28 (45.9)			36 (59.0)	25 (41.0)
Others	22	13 (59.1)	9 (40.9)			9 (40.9)	13 (59.1)
Unknown	15	13 (86.7)	2 (13.2)			12 (80.0)	3 (20.0)
AFIP-Miettinen risk classification
Very low-low risk	104	72 (69.2)	32 (30.8)	2.952	0.086	67 (64.4)	37 (35.6)	3.927	0.048^*
Moderate-high risk	39	21 (53.8)	18 (46.2)			18 (46.1)	21 (53.9)
Unknown	30	24 (80.0)	6 (20.0)			24 (80.0)	6 (20.0)

^*; HPF: high-power field.